Acta Diabetologica

, Volume 47, Issue 4, pp 315–323 | Cite as

STZ-induced skeletal muscle atrophy is associated with increased p65 content and downregulation of insulin pathway without NF-κB canonical cascade activation

  • Andrew R. Kelleher
  • Timothy J. Fairchild
  • Stefan KeslacyEmail author
Original Article


Type 1 diabetes mellitus (DM)-induced skeletal muscle atrophy is associated with an increased incidence in morbidity and mortality. Although the precise mechanism of diabetes-induced skeletal muscle atrophy remains to be established, several NF-κB-dependent pro-inflammatory genes have been identified as potential therapeutic targets. Moreover, activation of NF-κB has previously been shown to be required for cytokine-induced loss of skeletal muscle proteins. Therefore, we investigated activation of the NF-κB canonical pathway, concomitant to insulin signaling activation in skeletal muscle from diabetes-induced rats. Ten rats injected with streptozotocin (STZ) 4 weeks prior to tissue extraction were compared to 10 control rats. Using total, cytosolic and nuclear protein extracts from hindlimb muscles: soleus (SOL), extensor digitorum longus (EDL), gastrocnemius (GM) and liver tissue, we assessed key proteins important for the activation of both NF-κB and insulin pathways. Insulin blood concentration decreased to 3.9 ± 1.2 mU/ml following STZ-injection resulting in hyperglycemia (17.9 ± 0.7 mmol/l). SOL, EDL and GM mass decreased, and liver mass increased following STZ injection. NF-κB/p65 content in SOL, GM and liver increased in STZ-injected rats, without any change in IκB degradation or IKK phosphorylation. Muscle NF-κB/p65 remained bound to IκB and did not translocate or bind to DNA. Although the canonical NF-κB cascade was not activated, STZ induced a decrease in insulin pathway proteins including insulin receptor (IR) and substrate (IRS-1) content and phosphorylation compared to control animals. A downregulation of insulin pathway proteins and muscle atrophy occurred in response to STZ administration, and despite increased p65 content, STZ treatment did not activate the canonical NF-κB cascade. Therefore, it is unlikely that hyperglycemia initiates skeletal muscle atrophy via activation of the NF-κB canonical pathway.


STZ p65 NF-κB Insulin Skeletal muscle 



We thank Dr. Keith Deruisseau for his technical assistance. This work was supported by funding from Syracuse University.


  1. 1.
    Cnop M et al (2005) Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl 2):S97–107Google Scholar
  2. 2.
    Frier BC, Noble EG, Locke M (2008) Diabetes-induced atrophy is associated with a muscle-specific alteration in NF-kappaB activation and expression. Cell Stress Chaperones 13(3):287–296CrossRefPubMedGoogle Scholar
  3. 3.
    Ortis F et al (2008) Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 51(7):1213–1225CrossRefPubMedGoogle Scholar
  4. 4.
    Ramana KV et al (2004) Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 53(11):2910–2920CrossRefPubMedGoogle Scholar
  5. 5.
    Wang CY, She JX (2008) SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes Metab Res Rev 24(2):93–102CrossRefPubMedGoogle Scholar
  6. 6.
    Delano MJ, Moldawer LL (2006) The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 21(1):68–81CrossRefPubMedGoogle Scholar
  7. 7.
    Frost RA, Lang CH (2008) Regulation of muscle growth by pathogen-associated molecules. J Anim Sci 86(14 Suppl):E84–E93PubMedGoogle Scholar
  8. 8.
    Glass DJ (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37(10):1974–1984PubMedGoogle Scholar
  9. 9.
    Hunter RB et al (2002) Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. Faseb J 16(6):529–538CrossRefPubMedGoogle Scholar
  10. 10.
    Jeschke MG et al (2007) Gut mucosal homeostasis and cellular mediators after severe thermal trauma and the effect of insulin-like growth factor-I in combination with insulin-like growth factor binding protein-3. Endocrinology 148(1):354–362CrossRefPubMedGoogle Scholar
  11. 11.
    Frost RA et al (2007) Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am J Physiol Endocrinol Metab 292(2):E501–E512CrossRefPubMedGoogle Scholar
  12. 12.
    Melloul D (2008) Role of NF-kappaB in beta-cell death. Biochem Soc Trans 36(Pt 3):334–339CrossRefPubMedGoogle Scholar
  13. 13.
    Karin M, Delhase M (2000) The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 12(1):85–98CrossRefPubMedGoogle Scholar
  14. 14.
    Gilmore TD (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25(51):6680–6684CrossRefPubMedGoogle Scholar
  15. 15.
    Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006(357):re13Google Scholar
  16. 16.
    Rothwarf DM et al (1998) IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395(6699):297–300CrossRefPubMedGoogle Scholar
  17. 17.
    Cai D et al (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119(2):285–298CrossRefPubMedGoogle Scholar
  18. 18.
    Judge AR et al (2007) Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy. Am J Physiol Cell Physiol 292(1):C372–C382CrossRefPubMedGoogle Scholar
  19. 19.
    Wyke SM, Tisdale MJ (2005) NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 92(4):711–721CrossRefPubMedGoogle Scholar
  20. 20.
    Yerneni KK et al (1999) Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48(4):855–864CrossRefPubMedGoogle Scholar
  21. 21.
    Bi Y et al (2008) Effect of early insulin therapy on nuclear factor kappaB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats. Acta Diabetol 45(3):167–178CrossRefPubMedGoogle Scholar
  22. 22.
    Baldwin AS Jr (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649–683Google Scholar
  23. 23.
    Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44(12):2115–2133CrossRefPubMedGoogle Scholar
  24. 24.
    Keslacy S et al (2007) Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol Pharmacol 71(2):609–618CrossRefPubMedGoogle Scholar
  25. 25.
    Guttridge DC et al (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289(5488):2363–2366CrossRefPubMedGoogle Scholar
  26. 26.
    Pirola L et al (2003) Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. J Biol Chem 278(18):15641–15651CrossRefPubMedGoogle Scholar
  27. 27.
    Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87(1):99–109CrossRefPubMedGoogle Scholar
  28. 28.
    Kameyama N et al (2008) Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim Biophys Acta 1782(5):355–360PubMedGoogle Scholar
  29. 29.
    Lin SB et al (2000) In vitro and in vivo suppression of growth of rat liver epithelial tumor cells by antisense oligonucleotide against protein kinase C-alpha. J Hepatol 33(4):601–608CrossRefPubMedGoogle Scholar
  30. 30.
    Weisberg SP et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112(12):1796–1808PubMedGoogle Scholar
  31. 31.
    Rabe K et al (2008) Adipokines and insulin resistance. Mol Med 14(11–12):741–751PubMedGoogle Scholar
  32. 32.
    Schurr A et al (2001) Preischemic hyperglycemia-aggravated damage: evidence that lactate utilization is beneficial and glucose-induced corticosterone release is detrimental. J Neurosci Res 66(5):782–789CrossRefPubMedGoogle Scholar
  33. 33.
    Martin A et al (2006) Why does acute hyperglycemia worsen the outcome of transient focal cerebral ischemia? Role of corticosteroids, inflammation, and protein O-glycosylation. Stroke 37(5):1288–1295CrossRefPubMedGoogle Scholar
  34. 34.
    Garside H et al (2004) Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 279(48):50050–50059CrossRefPubMedGoogle Scholar
  35. 35.
    Wilson GL, Leiter EH (1990) Streptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetes. Curr Top Microbiol Immunol 156:27–54Google Scholar
  36. 36.
    Schnedl WJ et al (1994) STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43(11):1326–1333CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Andrew R. Kelleher
    • 1
  • Timothy J. Fairchild
    • 1
  • Stefan Keslacy
    • 1
    Email author
  1. 1.Department of Exercise ScienceSyracuse UniversitySyracuseUSA

Personalised recommendations